DeepCure Recruits US Urology and Circulatory Specialist SAB

[Asia Economy Reporter Hyungsoo Park] DeepCure, a bio-venture developing renal denervation (RDN) medical devices, announced on the 24th that it has recruited world-renowned scholars Jeffrey Kadeedu, professor at the University of Texas Southwestern Medical Center (UTSW), and Brian Kim, professor at Stanford University School of Medicine, as members of its Scientific Advisory Board (SAB).

A DeepCure official stated, "With the participation of these two medical professionals who have expertise and extensive experience in the fields of urology and cardiology, we will be able to accelerate the clinical trials." He added, "We will actively cooperate with these two scholars to ensure the clinical success of the RDN device 'HyperQure,' for which we recently submitted an Investigational Device Exemption (IDE) to the Ministry of Food and Drug Safety."

Professor Jeffrey Kadeedu is a key opinion leader (KOL) in the field of innovative medical devices. He currently serves as a professor of urology and radiology at the University of Texas Southwestern Medical Center and chairs the Robotics Committee. He is the associate editor of the journal Neurourology and Urodynamics and an editor of the Survey Section of the Journal of Urology. He has published over 290 papers related to urology.

Professor Brian Kim graduated from New York University School of Medicine and currently works as a cardiology specialist at Stanford University School of Medicine. His specialties include internal medicine, heart disease, and interventional cardiology.

DeepCure is developing the world's first laparoscopic RDN medical device. In March, it obtained a U.S. patent for the RDN medical device for resistant hypertension treatment. Starting domestic clinical trials this year, it plans to begin global clinical trials in earnest next year.

This content was produced with the assistance of AI translation services.